This product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the KYSE-30 human esophageal squamous cell carcinoma line, designed for loss-of-function studies of the ABCB10 gene. ABCB10 was targeted using CRISPR/Cas9-mediated gene disruption, generating a heterogeneous pool of cells with stable target-gene inactivation. As a polyclonal stock, the edited population preserves diverse editing events without clonal selection, providing a robust and convenient model for functional analyses in a physiologically relevant cancer background.
KYSE-30 cells originate from a human esophageal squamous cell carcinoma, representing a widely used epithelial malignancy model. These cells retain characteristic features of esophageal cancer, including dysregulated proliferation, metabolic reprogramming, and altered stress responses. The epithelial origin and genomic context of this line make it particularly suited for examining mitochondrial processes, heme metabolism, and redox homeostasis in the setting of squamous cell carcinoma.
ABCB10 encodes an inner mitochondrial membrane transporter critical for heme biosynthesis and iron homeostasis. The protein physically interacts with mitoferrin-1 (SLC25A37) to mediate iron import into the mitochondrial matrix, where ferrochelatase (FECH) catalyzes the terminal step of heme synthesis. ABCB10 expression is positively regulated by the transcription factor GATA1, hypoxia-inducible factors, and NFE2L2, positioning it at a nexus of oxygen sensing and antioxidant defense. Downstream, ABCB10 activity supports heme-dependent proteins, mitochondrial respiratory complex function, and the induction of antioxidant enzymes. Disruption of ABCB10 therefore impairs iron-sulfur cluster biogenesis, heme output, and mitochondrial integrity, leading to elevated oxidative stress.
In esophageal squamous cell carcinoma, reprogrammed mitochondrial metabolism and iron handling are often linked to tumor growth and stress adaptation. The KYSE-30 ABCB10 knockout polyclonal cells enable direct interrogation of how loss of this transporter compromises heme biosynthesis and sensitizes cancer cells to oxidative damage. This model is valuable for exploring mitochondrial dysregulation in an epithelial cancer context and for dissecting crosstalk between heme metabolism, respiratory chain activity, and antioxidant defense mechanisms that may influence tumor progression.
This knockout model is suited for a range of experimental applications, including quantitative heme measurements, intracellular iron level assays, mitochondrial function profiling by Seahorse analysis, reactive oxygen species (ROS) detection, and western blotting for heme synthesis enzymes such as ALAS1 and FECH. Researchers can employ these cells to study mitochondrial iron trafficking, heme-regulated signaling, and oxidative stress responses in esophageal cancer. The polyclonal population also facilitates pooled CRISPR screening follow-ups and drug sensitivity testing in the setting of mitochondrial dysfunction. For additional information or ordering inquiries, please contact Ascent Research.
